For the evaluation of patients with recurrent infection for the possibility of IgA deficiency (IgAD). Patients with IgA deficiency may develop antibodies against IgA that make them susceptible to adverse reactions to blood products including intravenous immunoglobulin.
ELISA using human polyclonal IgA coupled to the solid phase. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
5-8 business days from receipt of specimen
|Specimen Type||Order Code||CPT Code||NY Approved||Volume||Assay Range||Special Instructions|
1 mL (min. 100 uL)
Reported in U/mL. Normal, healthy individuals who do not have anti-IgA antibodies contain <99 U/mL. The reportable range is 16-1000 U/mL.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
- Hammarstrom L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol. 2000; 120:225-231.
- Burrows D, Cooper MD: IgA Deficiency. Adv Immunol 1997; 65:245-276.
- Aghamohammadi A, Mohammadi J, Parvaneh N, Rezael N, Moin M, Espanol T. and Hammarstrom L. Progression of Selective IgA Deficiency to Common Variable Immunodeficiency. Int Arch Allergy Immunol 2008;147:87-92.
- Horn J, Thon V, Bartonkova D, Salzer U, warnatz K, Schlesier M, Peter H, and Grimbacher B. Anti-IgA antibodies in Common Variable Immunodeficiency (CVID): Diagnostic workup and therapeutic strategy. Clin Immunol 2007;122:156-162.